GRI BIO, Inc. Files 8-K
Ticker: GRI · Form: 8-K · Filed: Jul 26, 2024 · CIK: 1824293
Sentiment: neutral
Topics: sec-filing, corporate-event, pharmaceuticals
TL;DR
GRI BIO (formerly Vallon Pharma) filed an 8-K on 7/26/24 for other events/financials.
AI Summary
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on July 26, 2024, to report other events and financial statements. The company, incorporated in Delaware with its principal executive offices in La Jolla, CA, operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates GRI BIO, Inc. is making a formal disclosure to the SEC regarding significant events or financial updates, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine SEC filing for corporate events and does not inherently signal significant financial distress or positive news.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- GRI BIO, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- July 26, 2024 (date) — Date of report
- La Jolla, CA (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What specific 'Other Events' are being reported by GRI BIO, Inc. in this 8-K filing?
The filing indicates 'Other Events' as a category, but the specific details of these events are not provided in the excerpt.
When did GRI BIO, Inc. change its name from Vallon Pharmaceuticals, Inc.?
The date of the name change from Vallon Pharmaceuticals, Inc. to GRI BIO, Inc. was September 10, 2020.
What is the primary business sector for GRI BIO, Inc.?
GRI BIO, Inc. is classified under the Pharmaceutical Preparations sector, SIC code 2834.
Where are GRI BIO, Inc.'s principal executive offices located?
The principal executive offices of GRI BIO, Inc. are located at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
What is the SEC file number for GRI BIO, Inc.?
The SEC file number for GRI BIO, Inc. is 001-40034.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-07-26 16:07:43
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
- $2,644,609 — s Agreement"), to up to an aggregate of $2,644,609 of Shares, which does not include the S
- $961,272 — gate gross sales price of approximately $961,272 that have been sold to date under the S
Filing Documents
- val-20240726.htm (8-K) — 24KB
- ex51_mintzopinion1.htm (EX-5.1) — 15KB
- mintzlogo.jpg (GRAPHIC) — 6KB
- picture1.jpg (GRAPHIC) — 4KB
- val-20240726_g1.jpg (GRAPHIC) — 16KB
- val-20240726_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000094.txt ( ) — 210KB
- val-20240726.xsd (EX-101.SCH) — 2KB
- val-20240726_lab.xml (EX-101.LAB) — 23KB
- val-20240726_pre.xml (EX-101.PRE) — 13KB
- val-20240726_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On July 26, 2024, GRI Bio, Inc. (the "Company") filed a prospectus supplement to increase the maximum number of shares (the "Shares") of the Company's common stock, par value $0.0001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated May 20, 2024 (the "Sales Agreement"), to up to an aggregate of $2,644,609 of Shares, which does not include the Shares having an aggregate gross sales price of approximately $961,272 that have been sold to date under the Sales Agreement. Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to the legality of the issuance and sale of the Shares
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 23.1 Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 26, 2024 GRI BIO, INC. By: /s/ Leanne Kelly Name: Leanne Kelly Title: Chief Financial Officer